ACADIA Pharmaceuticals Inc. reiterated earnings guidance for the full year 2024. For the year, the company expects DAYBUE net product sales guidance in the range of $370 million to $420 million. NUPLAZID net product sales guidance in the range of $560 million to $590 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.09 USD | -0.72% | -1.18% | -51.80% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.80% | 2.49B | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Acadia Pharmaceuticals Inc. Reiterates Earnings Guidance for the Full Year 2024